CY1124831T1 - Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων - Google Patents

Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων

Info

Publication number
CY1124831T1
CY1124831T1 CY20211100595T CY211100595T CY1124831T1 CY 1124831 T1 CY1124831 T1 CY 1124831T1 CY 20211100595 T CY20211100595 T CY 20211100595T CY 211100595 T CY211100595 T CY 211100595T CY 1124831 T1 CY1124831 T1 CY 1124831T1
Authority
CY
Cyprus
Prior art keywords
androgen receptor
receptor modulator
crystal forms
modulator
trifluoromethylpyridin
Prior art date
Application number
CY20211100595T
Other languages
English (en)
Inventor
Anna Dilhas
Ouathek Ouerfelli
Nicholas D. Smith
Mark R. Herbert
Original Assignee
Aragon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124831(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals, Inc. filed Critical Aragon Pharmaceuticals, Inc.
Publication of CY1124831T1 publication Critical patent/CY1124831T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Στο παρόν περιγράφονται άμορφες και κρυσταλλικές μορφές του ρυθμιστή υποδοχέα ανδρογόνων 4-[7-(6-κυανο-5-τριφθορομεθυλοπυριδιν-3-υλο)-8-οξο-6-θειοξο-5,7-διαζασπιρο[3,4]οκτ-5-υλο]-2-φθορο-Ν-μεθυλοβενζαμίδιο. Επίσης περιγράφονται φαρμακευτικές συνθέσεις κατάλληλες για χορήγηση σε ένα θηλαστικό οι οποίες περιλαμβάνουν το ρυθμιστή υποδοχέα ανδρογόνων, και μέθοδοι χρήσης του ρυθμιστή υποδοχέα ανδρογόνων, μόνου και σε συνδυασμό με άλλες ενώσεις, για την αγωγή νόσων ή παθήσεων που σχετίζονται με την δραστικότητα του υποδοχέα ανδρογόνων.
CY20211100595T 2012-06-07 2021-07-02 Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων CY1124831T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
PCT/US2013/044116 WO2013184681A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
EP18157435.1A EP3348553B1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
EP13800681.2A EP2858985B1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number Publication Date
CY1124831T1 true CY1124831T1 (el) 2022-03-24

Family

ID=49712550

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20181100712T CY1120393T1 (el) 2012-06-07 2018-07-06 Κρυσταλλικες μορφες διαμορφωτη υποδοχεα ανδρογονων
CY20201100901T CY1123427T1 (el) 2012-06-07 2020-09-23 Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn
CY20211100595T CY1124831T1 (el) 2012-06-07 2021-07-02 Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20181100712T CY1120393T1 (el) 2012-06-07 2018-07-06 Κρυσταλλικες μορφες διαμορφωτη υποδοχεα ανδρογονων
CY20201100901T CY1123427T1 (el) 2012-06-07 2020-09-23 Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn

Country Status (42)

Country Link
US (8) US9481663B2 (el)
EP (4) EP3533792B1 (el)
JP (3) JP6182209B2 (el)
KR (2) KR102195916B1 (el)
CN (3) CN104619692A (el)
AU (3) AU2013271751B2 (el)
BR (1) BR112014030678A2 (el)
CA (4) CA3008345C (el)
CL (1) CL2014003331A1 (el)
CO (1) CO7240407A2 (el)
CR (2) CR20190331A (el)
CY (3) CY1120393T1 (el)
DK (3) DK2858985T3 (el)
EA (3) EA201992010A1 (el)
EC (1) ECSP14030098A (el)
ES (3) ES2670683T3 (el)
FR (1) FR21C1050I1 (el)
GT (1) GT201400283A (el)
HK (2) HK1210175A1 (el)
HR (3) HRP20180902T1 (el)
HU (4) HUE038082T2 (el)
IL (4) IL236055A0 (el)
IN (1) IN2014DN10084A (el)
LT (4) LT2858985T (el)
ME (2) ME03815B (el)
MX (1) MX356754B (el)
MY (1) MY187500A (el)
NI (1) NI201400142A (el)
NO (1) NO2021046I1 (el)
NZ (2) NZ717683A (el)
PE (2) PE20200725A1 (el)
PH (2) PH12014502714A1 (el)
PL (3) PL3533792T3 (el)
PT (3) PT2858985T (el)
RS (3) RS60617B1 (el)
SG (3) SG11201408140QA (el)
SI (3) SI3533792T1 (el)
TR (1) TR201808939T4 (el)
TW (1) TWI532732B (el)
UA (2) UA123142C2 (el)
WO (1) WO2013184681A1 (el)
ZA (1) ZA201500076B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP4282449A3 (en) 2009-01-12 2024-02-28 University Of Massachusetts Lowell Polyisobutylene-based polyurethanes
AP2014007657A0 (en) 2011-12-16 2014-05-31 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
KR102195916B1 (ko) 2012-06-07 2020-12-30 아라곤 파마슈티컬스, 인코포레이티드 안드로겐 수용체 조절제의 결정 형태
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
NZ745682A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JP2015535538A (ja) 2012-11-21 2015-12-14 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 高強度ポリイソブチレンポリウレタン
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP3186247B1 (en) * 2014-08-26 2021-03-03 Astar Biotech LLC Protein kinase inhibitors
UA121123C2 (uk) 2014-12-05 2020-04-10 Араґон Фармасьютікалз, Інк. Протиракові композиції
EP3925598A1 (en) 2014-12-05 2021-12-22 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
CN107113952B (zh) 2014-12-19 2019-08-27 路创技术有限责任公司 具有多个发光二极管驱动器的多通道照明器具
EP3463377A1 (en) 2016-06-03 2019-04-10 Aragon Pharmaceuticals, Inc. Anticancer compositions
US11149017B2 (en) 2016-12-13 2021-10-19 Watson Laboratories Inc. Solid state forms of apalutamide
US10526429B2 (en) 2017-03-07 2020-01-07 Cardiac Pacemakers, Inc. Hydroboration/oxidation of allyl-terminated polyisobutylene
EP3668912B1 (en) 2017-08-17 2021-06-30 Cardiac Pacemakers, Inc. Photocrosslinked polymers for enhanced durability
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER
WO2019135254A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
US11472911B2 (en) 2018-01-17 2022-10-18 Cardiac Pacemakers, Inc. End-capped polyisobutylene polyurethane
WO2019242439A1 (zh) 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
US20220281836A1 (en) * 2019-08-22 2022-09-08 Dr. Reddy's Laboratories Limited Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
US20230312507A1 (en) 2020-09-04 2023-10-05 Synthon B.V. Improved process for preparation of apalutamide
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634A (zh) * 2022-10-17 2022-12-30 上海博悦生物科技有限公司 一种阿帕他胺的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2007245022A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
PT2656842T (pt) 2006-03-27 2016-10-04 Univ California Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
CA2787083C (en) * 2010-02-16 2018-05-22 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
KR102195916B1 (ko) 2012-06-07 2020-12-30 아라곤 파마슈티컬스, 인코포레이티드 안드로겐 수용체 조절제의 결정 형태
WO2019242439A1 (zh) 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途

Also Published As

Publication number Publication date
DK2858985T3 (en) 2018-05-28
PL3533792T3 (pl) 2021-11-29
CN104619692A (zh) 2015-05-13
MX2014015005A (es) 2015-09-04
CN105693692A (zh) 2016-06-22
ME03081B (me) 2019-01-20
CO7240407A2 (es) 2015-04-17
PE20150631A1 (es) 2015-05-11
JP6345821B2 (ja) 2018-06-20
HRP20180902T1 (hr) 2018-08-24
AU2017279807A1 (en) 2018-01-25
AU2013271751A1 (en) 2014-12-18
IN2014DN10084A (el) 2015-08-21
AU2017200298B2 (en) 2017-09-28
ES2809738T3 (es) 2021-03-05
RS57370B1 (sr) 2018-08-31
LT3533792T (lt) 2021-07-26
PH12014502714B1 (en) 2015-02-02
EP2858985B1 (en) 2018-04-18
SI3533792T1 (sl) 2021-11-30
US20200115361A1 (en) 2020-04-16
EA028791B1 (ru) 2017-12-29
PL3348553T3 (pl) 2021-02-08
US20150133481A1 (en) 2015-05-14
ES2875932T3 (es) 2021-11-11
DK3533792T3 (da) 2021-06-28
CA3055660A1 (en) 2013-12-12
CA3008345C (en) 2019-10-22
EP3533792A1 (en) 2019-09-04
SG10201610249TA (en) 2017-02-27
PH12014502714A1 (en) 2015-02-02
EP2858985A1 (en) 2015-04-15
TW201402561A (zh) 2014-01-16
US20210163441A1 (en) 2021-06-03
SG10201610248SA (en) 2017-02-27
SG11201408140QA (en) 2015-01-29
PH12016501470B1 (en) 2017-07-10
US20180258067A1 (en) 2018-09-13
HK1210175A1 (en) 2016-04-15
LT3348553T (lt) 2020-09-25
US10556882B2 (en) 2020-02-11
NZ702203A (en) 2016-09-30
CY1120393T1 (el) 2019-07-10
ES2670683T3 (es) 2018-05-31
HUE050357T2 (hu) 2020-11-30
AU2017200298A1 (en) 2017-02-02
DK3348553T3 (da) 2020-07-27
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
JP2015518890A (ja) 2015-07-06
PT2858985T (pt) 2018-07-10
US20190330182A1 (en) 2019-10-31
AU2013271751B2 (en) 2017-02-23
HUE054595T2 (hu) 2021-09-28
US9994545B2 (en) 2018-06-12
EA201992010A1 (ru) 2020-01-24
EP3348553A1 (en) 2018-07-18
EA201492272A1 (ru) 2015-05-29
HK1226066A1 (zh) 2017-09-22
CR20190331A (es) 2019-11-12
CA3114726A1 (en) 2013-12-12
JP6182209B2 (ja) 2017-08-16
KR102195916B1 (ko) 2020-12-30
JP2018141009A (ja) 2018-09-13
PE20200725A1 (es) 2020-07-21
WO2013184681A1 (en) 2013-12-12
HUE038082T2 (hu) 2018-09-28
RS61988B1 (sr) 2021-07-30
CR20140549A (es) 2015-04-06
MX356754B (es) 2018-06-11
HRP20210909T1 (hr) 2021-09-03
ECSP14030098A (es) 2016-01-29
NZ717683A (en) 2018-04-27
US10766875B2 (en) 2020-09-08
LTPA2021525I1 (el) 2021-11-25
AU2017279807B2 (en) 2018-11-08
MY187500A (en) 2021-09-24
PT3348553T (pt) 2020-09-28
GT201400283A (es) 2017-07-03
KR20190132543A (ko) 2019-11-27
BR112014030678A2 (pt) 2017-06-27
IL267608A (en) 2019-08-29
US9481663B2 (en) 2016-11-01
CY1123427T1 (el) 2021-12-31
IL259738A (en) 2018-07-31
UA123142C2 (uk) 2021-02-24
ME03815B (me) 2021-04-20
FR21C1050I1 (fr) 2021-12-10
EP3348553B1 (en) 2020-07-08
US10526310B2 (en) 2020-01-07
IL236055A0 (en) 2015-02-01
US10308630B2 (en) 2019-06-04
NO2021046I1 (no) 2021-11-02
HRP20201387T1 (hr) 2020-11-27
SI3348553T1 (sl) 2020-11-30
CA2875767C (en) 2018-08-14
EA201791592A1 (ru) 2018-01-31
CN113135892A (zh) 2021-07-20
TR201808939T4 (tr) 2018-07-23
HUS2100047I1 (hu) 2021-11-29
US20200354335A1 (en) 2020-11-12
CA3008345A1 (en) 2013-12-12
EP2858985A4 (en) 2016-05-25
PT3533792T (pt) 2021-06-07
IL275413A (en) 2020-07-30
LT2858985T (lt) 2018-09-25
US20170001977A1 (en) 2017-01-05
UA115665C2 (uk) 2017-12-11
CL2014003331A1 (es) 2016-03-04
KR102062024B1 (ko) 2020-01-03
KR20150021993A (ko) 2015-03-03
SI2858985T1 (sl) 2018-12-31
EP3533792B1 (en) 2021-05-05
IL259738B (en) 2021-06-30
ZA201500076B (en) 2016-10-26
PH12016501470A1 (en) 2017-07-10
JP2017178923A (ja) 2017-10-05
TWI532732B (zh) 2016-05-11
CA2875767A1 (en) 2013-12-12
RS60617B1 (sr) 2020-09-30
US20190241539A1 (en) 2019-08-08
EA033956B1 (ru) 2019-12-13
EP3922629A1 (en) 2021-12-15
PL2858985T3 (pl) 2018-09-28

Similar Documents

Publication Publication Date Title
CY1124831T1 (el) Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
UY35678A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGO NISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
EA201492050A1 (ru) Модуляторы ядерного транспорта и их применение
ECSP099553A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides
MX2012011504A (es) Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa).
GT201500159A (es) Derivados de imidazopiridazina como moduladores del receptor gabaa
UY36054A (es) “CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENOPIRIDOPIRAZINADIONAS NOVEDOSAS”.
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
MX2017001869A (es) Formas cristalinas de un modulador de receptor de estrogeno.
TR201000689A1 (tr) Sefprozil içeren katı dozaj formlar.
GT201600004A (es) Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h- pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparación, y las formulaciones farmacéuticas que la contienen
EA201690236A1 (ru) Производные индол-3-карбинола
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
ECSP12012120A (es) Compuestos de pirazol como antagonistas de crth2.
CU24047B1 (es) Derivados de oxazina útiles en el tratamiento de los trastornos neurológicos
CR20120083A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurologicos